Dr. Charles J. Ganley, a top Food and Drug Administration official, said the agency was "revisiting the risks and benefits of the use of these drugs in children," especially those under 2, The New York Times reported in Friday's editions.
A group of pediatricians and public health officials asked the agency Thursday to bar drug manufacturers from marketing such remedies as Toddler's Dimetapp, Infant Triaminic and Little Colds to children under 6.
